AB1765-HPR APPLICATION OF THE EULAR SYSTEMIC SCLEROSIS IMPACT OF DISEASE (SCLEROID) QUESTIONNAIRE IN AN ITALIAN COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS: ANALYSIS OF PATIENT-REPORTED OUTCOMES AND THEIR ASSOCIATION WITH MAIN DISEASE FEATURES
Authors: I. Bisconti, D. M. Reza Beigi, G. Pellegrino, M. Cadar, F. R. DI Ciommo, K. Stefanantoni, S. Truglia, F. Conti, V. Riccieri
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Systemic sclerosis (SSc) is characterized by a chronic and frequently progressive course and by a high patient-to-patient variability. Due to the lack of disease-specific, patient-reported outcome measures for use in clinical trials and in clinical practice, EULAR recently validated the Systemic Sclerosis Impact of Disease (ScleroID) questionnaire, calculated as a composite score of 10 different health dimensions with Numeric Rating Scales (NRS) from 0 to 10 (from best to worst)(Figure 1). For each dimension, the NRS score is multiplied by the specific weight for its item and the weighted scores are summed up. <h3>Objectives</h3> The aim of this study was to apply ScleroID questionnaire to an Italian cohort of patients affected by SSc and to find any possible association with their main demographical, clinical and serological features. <h3>Methods</h3> 55 consecutive patients with SSc (defined by 2013 ACR/EULAR criteria) were enrolled, ScleroID was administered. Socio-demographic variables and clinical features were recorded. Data were analyzed using GraphPad Prism 8 software. Wilcoxon nonparametric test was used to compare data. Spearman's rank correlation coefficient was used and Linear regression analysis (r correlation coefficient) was employed to identify significant correlations, defined by a p value &lt;0.05. <h3>Results</h3> The main demographic, clinical and serological features of the study population are shown in table 1. ScleroID total score median value of our patients was 42 (IQR 21-57). Significant associations were found among the presence of DU and higher values in the domains of Raynaud's phenomenon (p 0.03), impaired hand function (IHF)(p 0.005), pain (p 0.013), life choices (LC)(p 0.03) and body mobility (BM)(p 0.01). Anti-SCL70 positivity was associated with higher DU domain score (p 0.01). Diffuse SSc form was associated with higher values of IHF (p 0.006), pain (p 0.02), LC (p 0.002), BM (p 0.0005) and DU domains (p 0.003). Moreover, a positive correlation was found between mRSS and IHF (p 0.02), LC (p 0.006), BM (p 0.02) and DU (p 0.04), as well as between lower gastrointestinal symptoms domain and age (p 0.02). A higher ScleroID global score was associated with the diffuse SSc form (p 0.002), the use of immunosuppressive therapy (p 0.01) and the presence of DU (p&gt;0.0001). Finally, this last result was confirmed on multivariate analysis (p0.007). <h3>Conclusion</h3> Our results confirm the reliability of ScleroID questionnaire in the real life of ScS patients, highlighting the impact of an extensive cutaneous involvement and the presence of DU in several health quality dimensions. Thus ScleroID appears to be a valid and easy to perform tool, able to assess the disease activity by a patient reported outcome. <h3>Reference</h3> [1]Becker MO <i>et al</i>, Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire; Annals of the Rheumatic Diseases 2022 <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.